Association between genetic polymorphisms of the prostaglandin F2α receptor gene, and response to latanoprost in patients with glaucoma and ocular hypertension
Association between genetic polymorphisms of the prostaglandin F2α receptor gene, and response to latanoprost in patients with glaucoma and ocular hypertension
复制标题
DOI：
10.1136/bjophthalmol-2013-304267
复制
发表时间：
2014-04-01
影响因子：
4.1
通讯作者：
Sugiyama, Kazuhisa
中科院分区：
文献类型：
--
作者：
Sakurai, Mayumi;Higashide, Tomomi;Sugiyama, Kazuhisa
目的探讨拉坦前列素降低青光眼伴高眼压（OH）患者眼压是否与前列腺素F2 α (FP)受体基因单核苷酸多态性（snp）相关。方法对82例单眼接受拉坦前列素单药治疗的青光眼或OH患者，采用直接DNA测序或其他方法测定FP受体基因9个snp的基因型。IOP降低通过IOP降低百分比（% δ IOP）来评估，通过减去未治疗眼的IOP波动来估计。受试者按% δ IOP分为低反应组（% δ IOP= 10%）。分析了% δ IOP与FP受体基因snp的相关性。结果多元回归分析显示，rs12093097是唯一与%Delta IOP相关的显著因子（p=0.039）。在估计的单倍型中，一个仅在rs3753380中含有次要等位基因的单倍型，即使经过多次检验校正，也与低应答者显著相关（置换检验，p=0.037）。结论FP受体基因snp与青光眼或OH患者对拉坦前列素的反应有关。FP受体基因多态性可能影响拉坦前列素对这些患者眼压降低的程度。
Aim To examine whether intraocular pressure (IOP) reduction by latanoprost correlates with single nucleotide polymorphisms (SNPs) of the prostaglandin F2 alpha (FP) receptor gene in patients with glaucoma and ocular hypertension (OH).Methods The genotype of nine SNPs in the FP receptor gene was determined by direct DNA sequencing, or other techniques, in 82 patients with glaucoma or OH who were treated with latanoprost monotherapy in one eye. The IOP reduction was evaluated by the percent IOP reduction (%Delta IOP), estimated by subtracting IOP fluctuations in the untreated fellow eye. Subjects were classified by %Delta IOP into low responders (%Delta IOP= 10%). The correlation between %Delta IOP and SNPs in the FP receptor gene was analysed.Results Multiple regression analysis demonstrated that the rs12093097 was the only significant factor that correlated with %Delta IOP (p=0.039). Among estimated haplotypes, one haplotype that contained the minor allele only in rs3753380, was significantly correlated with low responders even after correction for multiple test (permutation test, p=0.037).Conclusions An association was found between SNPs of the FP receptor gene and the response to latanoprost in patients with glaucoma or OH. The FP receptor genetic polymorphism may influence the degree of IOP reduction by latanoprost in these patients.